Investors Asset Management of Georgia Inc. GA ADV held its position in Merck & Company, Inc. (NYSE:MRK) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,754 shares of the company’s stock at the end of the first quarter. Merck & accounts for about 1.1% of Investors Asset Management of Georgia Inc. GA ADV’s investment portfolio, making the stock its 16th largest position. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Merck & were worth $1,457,000 at the end of the most recent reporting period.
A number of other institutional investors have also bought and sold shares of MRK. Paragon Capital Management Ltd purchased a new position in Merck & during the first quarter valued at $608,000. Northeast Investment Management increased its stake in Merck & by 3.5% in the first quarter. Northeast Investment Management now owns 30,394 shares of the company’s stock worth $1,931,000 after buying an additional 1,034 shares during the period. Everett Harris & Co. CA increased its stake in Merck & by 0.4% in the first quarter. Everett Harris & Co. CA now owns 59,420 shares of the company’s stock worth $3,776,000 after buying an additional 254 shares during the period. Kanawha Capital Management LLC increased its stake in Merck & by 1.8% in the first quarter. Kanawha Capital Management LLC now owns 20,759 shares of the company’s stock worth $1,319,000 after buying an additional 372 shares during the period. Finally, HM Capital Management LLC increased its stake in Merck & by 0.4% in the first quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock worth $236,000 after buying an additional 15 shares during the period. Hedge funds and other institutional investors own 73.73% of the company’s stock.
Shares of Merck & Company, Inc. (NYSE MRK) traded down 0.84% during trading on Tuesday, hitting $62.31. 4,965,014 shares of the stock were exchanged. The stock has a 50-day moving average of $63.65 and a 200 day moving average of $63.78. The stock has a market cap of $170.43 billion, a P/E ratio of 33.74 and a beta of 0.80. Merck & Company, Inc. has a 12-month low of $57.18 and a 12-month high of $66.80.
Merck & (NYSE:MRK) last posted its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a return on equity of 25.75% and a net margin of 17.14%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the business earned $0.93 earnings per share. Equities analysts predict that Merck & Company, Inc. will post $3.87 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.99%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s dividend payout ratio is 76.11%.
TRADEMARK VIOLATION NOTICE: This news story was published by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2017/08/08/investors-asset-management-of-georgia-inc-ga-adv-continues-to-hold-position-in-merck-company-inc-mrk-updated-updated-updated.html.
MRK has been the topic of a number of research analyst reports. J P Morgan Chase & Co boosted their price target on shares of Merck & from $74.00 to $76.00 and gave the company an “overweight” rating in a research note on Thursday, May 11th. Zacks Investment Research downgraded shares of Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Credit Suisse Group reaffirmed a “buy” rating on shares of Merck & in a research note on Tuesday, June 13th. Vetr raised shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 target price on the stock in a research note on Monday, May 15th. Finally, Cowen and Company reissued a “market perform” rating and issued a $70.00 price objective (up from $68.00) on shares of Merck & in a research report on Thursday, May 11th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. Merck & has an average rating of “Hold” and an average target price of $69.80.
In related news, Director C Robert Kidder sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $63.54, for a total value of $317,700.00. Following the transaction, the director now owns 14,317 shares in the company, valued at $909,702.18. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.05% of the stock is owned by company insiders.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.